Oculis Holding AG

About Oculis Holding AG

Oculis is a global biopharmaceutical company dedicated to saving sight and improving eye care through innovative treatments. Their mission is to rethink ophthalmology by addressing key unmet medical needs in eye diseases with transformative therapies.

Products & Services

OCS-01:An OPTIREACH® formulation of high concentration dexamethasone eye drop, aimed at becoming the first non-invasive treatment for Diabetic Macular Edema (DME) and Post Ocular Surgery, addressing unmet needs for earlier intervention and suboptimal responders to anti-VEGF therapies.

OCS-02 (licaminlimab):An anti-TNFα eye drop candidate designed to treat ocular inflammation, with potential to transform the treatment paradigm for Dry Eye Disease (DED) and Uveitis using a precision medicine approach.

OCS-05:A novel first-in-class peptidomimetic small molecule, aimed at becoming a neuroprotective therapy for Acute Optic Neuritis and other neuro-ophthalmic diseases.

Specialties

Diabetic Macular Edema (DME) Dry Eye Disease (DED) Acute Optic Neuritis Post Ocular Surgery Uveitis Ocular Inflammation Neuroprotective Therapies OPTIREACH® Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 110000000 MR: - FA: $110 million FAN: 110000000	D: 2025-10-30 FD: 2025-10-30	5 investors
2	RT: Debt T: - FT: Debt	A: 100000000 MR: - FA: up to CHF 100 million FAN: 100000000	D: 2025-08-01 FD: 2025-08-01	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: 100 million FAN: 100000000	D: 2025-02-13 FD: 2025-02-13	4 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 59000000 MR: - FA: $59 million FAN: 59000000	D: 2024-04-22 FD: 2024-04-22	2 investors
5	RT: Public Offering of Ordinary Shares T: - FT: Public Offering of Ordinary Shares	A: 42000000 MR: - FA: $42.0 million FAN: 42000000	D: 2023-06-13 FD: 2023-06-13	7 investors
6	RT: Follow-on Public Offering T: - FT: Follow-on Public Offering	A: 5000000 MR: - FA: 5,000,000 ordinary shares FAN: 5000000	D: 2023-05-30 FD: 2023-05-30	7 investors

Underwritten Offering Latest

2025-10-30

$110.0M

5 investors (Pro only)

Debt 2025-08-01

$100.0M

Public Offering 2025-02-13

$100.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Riad Sherif

Chief Executive Officer

LinkedIn (Pro only)

G

Gudrun Bachmann

Chief Technology Officer

LinkedIn (Pro only)

S

Sylvia Cheung

Chief Financial Officer

LinkedIn (Pro only)

I

Isabelle de Chambrier

Chief Quality Officer

P

Páll Ragnar Jóhannesson

Chief Business Officer

S

Sharon Klier

Chief Development Officer

View 7 more team members with Pro

Unlock Full Team Directory

Recent News